Somatostatin Blocks GHRP's Ability to Activate the Brain's GH Control Center

Central somatostatin (octreotide) attenuated the GH secretagogue-induced activation of arcuate nucleus neurons, demonstrating that somatostatin can oppose GHRP action at the hypothalamic level.

Dickson, S L et al.·Neuroendocrinology·1997·Preliminary EvidenceAnimal StudyAnimal Study
RPEP-00404Animal StudyPreliminary Evidence1997RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Octreotide (somatostatin analog) attenuated GH secretagogue-induced Fos expression in the arcuate nucleus, showing somatostatin opposes GHRP action centrally.

Key Numbers

How They Did This

Conscious male rats received IV octreotide (100 µg) or saline 10 minutes before IV GH secretagogue injection. Brains were processed for Fos protein immunohistochemistry.

Why This Research Matters

Understanding that somatostatin can block GHRP effects in the brain explains why high somatostatin states (like elevated blood sugar) can reduce GHRP efficacy.

The Bigger Picture

This finding explains why GHRPs work best when somatostatin tone is low (fasting, nighttime) and less well after meals or in high-glucose states.

What This Study Doesn't Tell Us

Animal study using pharmacological somatostatin analog (octreotide) at a specific dose. Natural somatostatin dynamics may differ. Fos expression is an indirect marker.

Questions This Raises

  • ?Is the somatostatin-GHRP interaction at the hypothalamus clinically significant?
  • ?Can timing GHRP administration around somatostatin fluctuations optimize GH response?

Trust & Context

Key Stat:
Central GHRP blockade by somatostatin Octreotide pre-treatment significantly reduced GHRP-induced arcuate nucleus activation
Evidence Grade:
Moderate animal evidence with clear pharmacological demonstration in conscious rats.
Study Age:
Published in 1997, informing current understanding of optimal GHRP timing relative to meals and blood sugar.
Original Title:
Attenuation of the growth hormone secretagogue induction of Fos protein in the rat arcuate nucleus by central somatostatin action.
Published In:
Neuroendocrinology, 66(3), 188-94 (1997)
Database ID:
RPEP-00404

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Why does somatostatin matter for GHRP users?

Somatostatin is the body's natural GH suppressor. When somatostatin levels are high (after meals, high blood sugar), it opposes GHRP effects at both the pituitary and brain. This is why GHRPs work best when taken fasting.

What is octreotide?

Octreotide (Sandostatin) is a long-acting synthetic version of somatostatin used medically to suppress hormone secretion. In this study it was used as a research tool to demonstrate somatostatin's opposition to GHRP effects.

Read More on RethinkPeptides

Cite This Study

RPEP-00404·https://rethinkpeptides.com/research/RPEP-00404

APA

Dickson, S L; Viltart, O; Bailey, A R; Leng, G. (1997). Attenuation of the growth hormone secretagogue induction of Fos protein in the rat arcuate nucleus by central somatostatin action.. Neuroendocrinology, 66(3), 188-94.

MLA

Dickson, S L, et al. "Attenuation of the growth hormone secretagogue induction of Fos protein in the rat arcuate nucleus by central somatostatin action.." Neuroendocrinology, 1997.

RethinkPeptides

RethinkPeptides Research Database. "Attenuation of the growth hormone secretagogue induction of ..." RPEP-00404. Retrieved from https://rethinkpeptides.com/research/dickson-1997-attenuation-of-the-growth

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.